RxDoctor Payments Data

Anna Burson, MD

Family Medicine · Ardmore, OKNPI 1437109394

Payments from drug & device makers

$5,191in general payments, 2019–2025

Across 214 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$776
  • Johnson & Johnson$541
  • Novo Nordisk$524
  • AbbVie$431
  • GSK$364
  • Boehringer Ingelheim$286
  • plus $2K from 34 others

What the payments were for

  • Food & beverage$5,191100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,191 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$231,615
Medicare patients
490
Services billed
8,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide141$161,761
FarxigaDapagliflozin Propanediol61$81,071
JanuviaSitagliptin Phosphate48$57,727
JardianceEmpagliflozin42$54,659
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$44,961
RexultiBrexpiprazole12$41,707
EliquisApixaban29$24,703
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$18,551
XareltoRivaroxaban16$15,019
MounjaroTirzepatide13$14,367
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$12,716
Tresiba Flextouch U-100Insulin Degludec12$10,405
Tresiba Flextouch U-200Insulin Degludec14$9,842
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$9,828
Advair HfaFluticasone Propion/Salmeterol11$5,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$524$161,761141 claims
AstraZenecaFarxiga, Symbicort$776$85,00575 claims
MerckJanuvia$25$57,72748 claims
Boehringer IngelheimJardiance$286$54,65942 claims
GSKTrelegy Ellipta$364$44,96154 claims
Otsuka America Pharmaceutical, Inc.Rexulti$235$41,70712 claims
PfizerEliquis, Premarin$41$28,57343 claims
Johnson & JohnsonXarelto$541$15,01916 claims
Lilly USA, LLCMounjaro$107$14,36713 claims
AbbVieSynthroid$431$2,25037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →